The content on this site is intended for healthcare professionals only
At a press conference at EHA 2015, Dr Mesa presented new data from the Phase 3 PERSIST-1 study which showed that pacritinib is more effective than the best available therapy (BAT) at improving disease symptoms and quality of life (QoL) for patients with myelofibrosis.
Read the news story for more.
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
Guiding transplant decisions in multiple myeloma with MRD
Advancements in paediatric Acute lymphoblastic leukemia management
Choosing the right patients for transplant
Combination of zanubrutinib and venetoclax shows promise in high-risk TN CLL/SLL with del(17p) and/or TP53 mutation
Encouraging results using mismatched unrelated donors in stem cell transplantation
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Linvoseltamab induces deep and durable responses in patients with relapsed or refractory multiple myeloma
Adding nivolumab to R-GemOx shows enhanced efficacy in treating R/R large B-cell lymphoma
